EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Poll|November 14, 2014
Dime-Sized, Red, Scaly Patch: Your Dx?
A 58-year-old man asks about this painless lesion on his left third digit. It does not itch, burn, or sting and there are no other similar lesions. He had a history of basal cell carcinoma on the arm and several more recent actinic keratoses on his scalp. What’s your diagnosis?
Advertisement
A 58-year-old man asks about this painless lesion on his left third digit. It does not itch, burn, or sting and there are no other similar lesions. He had a history of basal cell carcinoma on the arm and several more recent actinic keratoses on his scalp.
What’s your diagnosis?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
9 Drugs Approved for Primary Care: Q3 2026
3
Multicomponent Strategies to Ease Vaccination Pain and Fear Across Ages
4
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
5